§ COMPARE REGULATORS

NMPA vs ANVISA: Medical Device Regulatory Comparison

Compare the medical device registration pathways, classification, and regulatory requirements of NMPA (China) vs ANVISA (Brazil).

NMPA

National Medical Products Administration (China)

China

China's NMPA regulates medical devices through CMDE (Center for Medical Device Evaluation) technical reviews. China uses a three-class risk-based system. Foreign manufacturers must appoint a Marketing

CLASSES

Class I, II, III

PATHWAY

NMPA Registration (CMDE review)

KEY FUNCTIONS
  • CMDE technical review
  • MAH (Marketing Authorization Holder) system
  • In-country testing requirements
  • Clinical trial oversight
  • NMPA registration certificates

ANVISA

Agência Nacional de Vigilância Sanitária (Brazil)

Brazil

ANVISA regulates medical devices in Brazil using a four-class risk-based system. Brazil is an MDSAP participating country. ANVISA requires a Brazilian Registration Holder (BRH) for foreign manufacture

CLASSES

Class I, II, III, IV

PATHWAY

ANVISA cadastro (Class I-II) / registro (Class III-IV)

KEY FUNCTIONS
  • Device registration (cadastro/registro)
  • Brazilian Registration Holder requirement
  • MDSAP participation
  • GMP (INMETRO) certification
  • ANVISA Technical Opinion

MedFlux monitors both NMPA and ANVISA in real time — every regulatory change, safety alert, and market signal delivered in under 90 seconds.

COMPARE LIVE DATA FREE →

§ OTHER COMPARISONS